A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson(Eisai (United States)), Jeffrey L. Cummings(University of California, Los Angeles), Scott Berry(Queen's University), Shobha Dhadda(Eisai (United States)), Robert J. Gordon(University of Windsor), Larisa Reyderman(Eisai (United States)), Donald A. Berry(Berry & Associates (United States)), June Kaplow(Eisai (United States)), Yong Zhang(Eisai (Japan)), Akihiko Koyama(Eisai (United States)), Martin Rabe(Eisai (United States)), Lynn D. Kramer(Eisai (United States)), Robert Lai(Eisai (United Kingdom)), Lars Lannfelt(BioArctic Neuroscience (Sweden)), Jinping Wang(Eisai (United States)), Heather Bradley(Eisai (United States))
Cited by 818
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k